RKDA
Income statement / Annual
Last year (2024), Arcadia Biosciences, Inc.'s total revenue was $5.05 M,
a decrease of 5.35% from the previous year.
In 2024, Arcadia Biosciences, Inc.'s net income was -$7.04 M.
See Arcadia Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$5.05 M |
$5.33 M |
$9.96 M |
$6.78 M |
$8.03 M |
$1.17 M |
$1.46 M |
$4.03 M |
$3.19 M |
$5.41 M |
| Cost of Revenue |
$2.96 M
|
$3.30 M
|
$9.80 M
|
$8.71 M
|
$5.20 M
|
$885,000.00
|
$661,000.00
|
$283,000.00
|
$895,000.00
|
$892,000.00
|
| Gross Profit |
$2.08 M
|
$2.03 M
|
$154,000.00
|
-$1.93 M
|
$2.84 M
|
$284,000.00
|
$803,000.00
|
$3.74 M
|
$2.29 M
|
$4.52 M
|
| Gross Profit Ratio |
0.41
|
0.38
|
0.02
|
-0.28
|
0.35
|
0.24
|
0.55
|
0.93
|
0.72
|
0.84
|
| Research and Development Expenses |
$53,000.00
|
$1.39 M
|
$1.51 M
|
$3.89 M
|
$7.96 M
|
$7.10 M
|
$6.07 M
|
$7.41 M
|
$8.66 M
|
$8.97 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$16.47 M
|
$13.57 M
|
$11.60 M
|
$10.65 M
|
$12.25 M
|
$11.12 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.64 M
|
$14.51 M
|
$18.05 M
|
$22.94 M
|
$16.47 M
|
$13.57 M
|
$11.60 M
|
$10.65 M
|
$12.25 M
|
$11.12 M
|
| Other Expenses |
-$3.96 M
|
$0.00
|
$33,000.00
|
$10.11 M
|
$105,000.00
|
$466,000.00
|
-$3.61 M
|
$281,000.00
|
$340,000.00
|
$521,000.00
|
| Operating Expenses |
$5.73 M
|
$15.90 M
|
$19.56 M
|
$26.83 M
|
$24.43 M
|
$20.67 M
|
$17.67 M
|
$18.06 M
|
$20.91 M
|
$20.09 M
|
| Cost And Expenses |
$12.66 M
|
$19.20 M
|
$29.36 M
|
$35.54 M
|
$29.63 M
|
$21.55 M
|
$18.33 M
|
$18.34 M
|
$21.81 M
|
$20.98 M
|
| Interest Income |
$782,000.00
|
$695,000.00
|
$289,000.00
|
$20,000.00
|
$47,000.00
|
$5,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$289,000.00
|
$20,000.00
|
$47,000.00
|
$5,000.00
|
$0.00
|
$747,000.00
|
$1.32 M
|
$2.66 M
|
| Depreciation & Amortization |
$113,000.00
|
$287,000.00
|
$1.36 M
|
$1.05 M
|
$662,000.00
|
$194,000.00
|
$154,000.00
|
$279,000.00
|
$304,000.00
|
$294,000.00
|
| EBITDA |
-$7.50 M |
-$13.58 M |
-$13.65 M |
-$23.27 M |
-$5.44 M |
-$28.67 M |
-$13.32 M |
-$14.66 M |
-$17.98 M |
-$14.98 M |
| EBITDA Ratio |
-1.49
|
-2.55
|
-1.37
|
-3.43
|
-0.68
|
-24.53
|
-9.1
|
-3.64
|
-5.64
|
-2.77
|
| Operating Income Ratio |
-0.72
|
-2.6
|
-1.95
|
-5.24
|
-2.69
|
-17.43
|
-11.52
|
-3.56
|
-5.84
|
-2.87
|
| Total Other Income/Expenses Net |
-$661,000.00
|
$708,000.00
|
$3.19 M
|
$19.39 M
|
$6.63 M
|
-$9.49 M
|
$3.40 M
|
-$1.37 M
|
-$979,000.00
|
-$2.37 M
|
| Income Before Tax |
-$4.31 M
|
-$13.16 M
|
-$15.60 M
|
-$16.13 M
|
-$6.15 M
|
-$28.87 M
|
-$13.47 M
|
-$15.68 M
|
-$19.60 M
|
-$17.93 M
|
| Income Before Tax Ratio |
-0.85
|
-2.47
|
-1.57
|
-2.38
|
-0.77
|
-24.7
|
-9.2
|
-3.89
|
-6.15
|
-3.31
|
| Income Tax Expense |
$8,000.00
|
$8,000.00
|
$14,000.00
|
$2,000.00
|
-$124,000.00
|
$2,000.00
|
$10,000.00
|
$26,000.00
|
$25,000.00
|
$26,000.00
|
| Net Income |
-$7.04 M
|
-$13.98 M
|
-$15.61 M
|
-$16.13 M
|
-$6.03 M
|
-$28.87 M
|
-$13.48 M
|
-$15.71 M
|
-$19.62 M
|
-$17.96 M
|
| Net Income Ratio |
-1.4
|
-2.62
|
-1.57
|
-2.38
|
-0.75
|
-24.7
|
-9.21
|
-3.9
|
-6.16
|
-3.32
|
| EPS |
-5.16 |
-11.3 |
-26.05 |
-30.33 |
-24.2 |
-181.5 |
-143.16 |
-291.38 |
-353.85 |
-503 |
| EPS Diluted |
-5.16 |
-11.3 |
-26.05 |
-30.33 |
-24.2 |
-181.5 |
-143.16 |
-291.38 |
-353.85 |
-503 |
| Weighted Average Shares Out |
$1.36 M
|
$1.24 M
|
$599,389.00
|
$532,015.00
|
$248,975.00
|
$159,077.00
|
$94,160.00
|
$53,905.00
|
$55,458.00
|
$35,698.00
|
| Weighted Average Shares Out Diluted |
$1.36 M
|
$1.24 M
|
$599,389.00
|
$532,015.00
|
$248,975.00
|
$159,077.00
|
$94,160.00
|
$53,905.00
|
$55,458.00
|
$35,698.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
